Bertrand Huard

List of Publications by Year
in descending order

69 papers	4,510 citations	147801 31 h-index	106344 65 g-index
70 all docs	70 docs citations	70 times ranked	5600 citing authors

#	Article	IF	Citations
1	Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.. Journal of Experimental Medicine, 1992, 176, 327-337.	8.5	331
2	Identification of proteoglycans as the APRIL-specific binding partners. Journal of Experimental Medicine, 2005, 201, 1375-1383.	8.5	323
3	APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood, 2008, 111, 2755-2764.	1.4	311
4	CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. European Journal of Immunology, 1995, 25, 2718-2721.	2.9	308
5	Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5744-5749.	7.1	224
6	Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Seminars in Immunopathology, 2008, 30, 425-437.	6.1	210
7	T Cell Costimulation by the TNF Ligand BAFF. Journal of Immunology, 2001, 167, 6225-6231.	0.8	198
8	Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. European Journal of Immunology, 1994, 24, 3216-3221.	2.9	189
9	APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. Journal of Clinical Investigation, 2008, 118, 2887-95.	8.2	175
10	Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. International Reviews of Immunology, 2017, 36, 3-19.	3.3	144
11	Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood, 2007, 109, 331-338.	1.4	138
12	BAFF production by antigen-presenting cells provides T cell co-stimulation. International Immunology, 2004, 16, 467-475.	4.0	134
13	KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature, 2000, 403, 325-328.	27.8	121
14	T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. European Journal of Immunology, 1996, 26, 1180-1186.	2.9	115
15	Selective Expression of FLIP in Malignant Melanocytic Skin Lesions. Journal of Investigative Dermatology, 2001, 117, 360-364.	0.7	97
16	Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 1227-1238.	6.1	91
17	A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. European Journal of Immunology, 2000, 30, 509-515.	2.9	89
18	Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood, 2011, 118, 1838-1844.	1.4	85

#	Article	IF	Citations
19	Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection. Journal of Immunology, 2006, 176, 61-67.	0.8	84
20	LAG-3 does not define a specific mode of natural killing in human. Immunology Letters, 1998, 61, 109-112.	2.5	73
21	The source of APRIL up-regulation in human solid tumor lesions. Journal of Leukocyte Biology, 2006, 80, 697-704.	3.3	68
22	APRIL Induces a Novel Subset of IgA+ Regulatory B Cells That Suppress Inflammation via Expression of IL-10 and PD-L1. Frontiers in Immunology, 2019, 10, 1368.	4.8	63
23	A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease. PLoS ONE, 2012, 7, e51892.	2.5	61
24	CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. Cancer Research, 2017, 77, 1097-1107.	0.9	59
25	Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR ?? lymphocytes. European Journal of Immunology, 2004, 34, 3456-3464.	2.9	58
26	Revisiting IL-6 antagonism in multiple myeloma. Critical Reviews in Oncology/Hematology, 2016, 105, 1-4.	4.4	53
27	A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. European Journal of Immunology, 2000, 30, 1665-1675.	2.9	40
28	Expression of inhibitory KIR is confined to CD8+ effector T?cells and limits their proliferative capacity. European Journal of Immunology, 2004, 34, 3413-3422.	2.9	39
29	Extralymphatic Tumors Prepare Draining Lymph Nodes to Invasion via a T-Cell Cross-Tolerance Process. Cancer Research, 2007, 67, 5009-5016.	0.9	39
30	Impaired CD40L signaling is a cause of defective IL-12 and TNF-Î± production in Sèzary syndrome: circumvention by hexameric soluble CD40L. Blood, 2005, 105, 219-225.	1.4	36
31	Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse. PLoS ONE, 2012, 7, e31837.	2.5	33
32	HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends in Immunology, 2007, 28, 437-441.	6.8	32
33	Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's Disease. Leukemia, 2007, 21, 1324-1327.	7.2	32
34	A proliferationâ€inducing ligandâ€“mediated antiâ€inflammatory response of astrocytes in multiple sclerosis. Annals of Neurology, 2019, 85, 406-420.	5.3	32
35	CD56^{bright} NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. European Journal of Immunology, 2010, 40, 3246-3254.	2.9	31
36	The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting. Journal of Autoimmunity, 2018, 95, 179-190.	6.5	31

#	Article	IF	Citations
37	Progression of fibrosis in patients with chronic viral hepatitis is associated with <scp>IL</scp>â€17⁺ neutrophils. Liver International, 2016, 36, 1116-1124.	3.9	30
38	Synovial tissues concentrate secreted APRIL. Arthritis Research and Therapy, 2009, 11, R144.	3.5	29
39	No Evidence That Soluble TACI Induces Signalling via Membrane-Expressed BAFF and APRIL in Myeloid Cells. PLoS ONE, 2013, 8, e61350.	2.5	27
40	Tumors that look for their springtime in APRIL. Critical Reviews in Oncology/Hematology, 2009, 72, 91-97.	4.4	26
41	KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation. European Journal of Immunology, 2001, 31, 1728-1735.	2.9	24
42	Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS ONE, 2015, 10, e0137044.	2.5	24
43	Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients. Blood Cancer Journal, 2018, 8, 66.	6.2	24
44	Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. European Journal of Cancer, 2008, 44, 2097-2100.	2.8	22
45	Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Research, 2007, 17, 169-176.	1.2	21
46	A CD40â€“CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. Journal of Molecular Medicine, 2006, 84, 785-797.	3.9	17
47	Abundant a proliferation-inducing ligand (APRIL)-producing macrophages contribute to plasma cell accumulation in immunoglobulin G4-related disease. Nephrology Dialysis Transplantation, 2019, 34, 960-969.	0.7	17
48	APRIL-producing eosinophils are involved in gastric MALT lymphomagenesis induced by Helicobacter sp infection. Scientific Reports, 2020, 10, 14858.	3.3	15
49	Direct Presentation of a Melanocyte-Associated Antigen in Peripheral Lymph Nodes Induces Cytotoxic CD8+ T Cells. Cancer Research, 2008, 68, 8410-8418.	0.9	12
50	Lymph node tumor metastases: more susceptible than primary tumors to CD8+ T-cell immune destruction. Trends in Immunology, 2009, 30, 569-573.	6.8	11
51	Absence of up-regulation for a proliferation-inducing ligand in Sjogren's sialadenitis lesions. Rheumatology, 2011, 50, 1211-1215.	1.9	10
52	Further analyses of APRIL/APRIL-receptor/glycosaminoglycan interactions by biochemical assays linked to computational studies. Glycobiology, 2021, 31, 772-786.	2.5	9
53	The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5. Blood Advances, 2021, 5, 4338-4351.	5.2	9
54	The number 13 of the family: a proliferation inducing ligand. Current Opinion in Immunology, 2021, 71, 132-137.	5.5	6

#	Article	IF	Citations
55	Advanced Molecular Dynamics Approaches to Model a Tertiary Complex APRIL/TACI with Long Glycosaminoglycans. Biomolecules, 2021, 11, 1349.	4.0	6
56	Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases. Experimental Hematology, 2008, 36, 533-534.	0.4	5
57	Heparan sulfate proteoglycans, Fc receptors, and DC suppression. Blood, 2008, 112, 915-916.	1.4	3
58	Evidence for a Repertoire of Functional Untolerized CD4⁺ T Cells Specific for Melanomaâ€Associated Antigens. Scandinavian Journal of Immunology, 2011, 74, 80-86.	2.7	3
59	Polarized Secretion of APRIL by the Tonsil Epithelium Upon Toll-Like Receptor Stimulation. Frontiers in Immunology, 2021, 12, 715724.	4.8	2
60	A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. European Journal of Immunology, 2000, 30, 509-515.	2.9	2
61	Expression of Inhibitory Receptors for MHC Class I Molecules on T Cells. Critical Reviews in Immunology, 2000, 20, 6.	0.5	2
62	Inhibition of Chondroitin Sulfate Proteoglycans by APRIL. Methods in Molecular Biology, 2021, 2248, 43-61.	0.9	2
63	Comment on â€œDendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironment Where Plasmablasts Matureâ€: FIGURE 1.. Journal of Immunology, 2009, 182, 5159-5159.	0.8	1
64	Buffy's, B cells, and membrane BAFF. Arthritis and Rheumatism, 2010, 62, 1557-1558.	6.7	1
65	Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica. Frontiers in Neurology, 2021, 12, 721877.	2.4	1
66	T cell tolerance to the skin: a central role for central tolerance. Seminars in Immunopathology, 2007, 29, 59-64.	6.1	0
67	Comment on â€œCutting Edge: FcR-Like 6 Is an MHC Class II Receptorâ€. Journal of Immunology, 2010, 185, 4965.1-4965.	0.8	0
68	FP304ABERRANT APRIL EXPRESSION IN TONSILLAR GERMINAL CENTER B CELLS IN IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii168-iii169.	0.7	0
69	Plasmocyte depletion in autoimmune diseases. , 2022, , 179-191.		0